Study finds heart failure medications highly cost-effective

March 28, 2013

A UCLA study shows that heart failure medications recommended by national guidelines are highly cost effective in saving lives and may also provide savings to the health care system.

Heart failure, a chronic, progressive disease, affects millions of individuals and results in considerable morbidity, the use of extensive , and substantial costs.

Currently published online, the study will also appear in the April 2 print issue of the Journal of the American College of Cardiology. Researchers studied the incremental health and cost benefits of three common heart failure medications that are recommended by national guidelines developed by organizations like the American College of Cardiology and American Heart Association.

This is one of the first studies analyzing the incremental cost effectiveness of heart failure medications and taking into account the very latest information, including the lower costs of generic versions of the medications. Researchers found that the combination of these therapies demonstrated the greatest gains in quality-adjusted life years for heart failure patients.

"We found that use of one or more of these key medications in combination was associated with significant health gains while at the same time being cost-effective or providing a cost-savings," said the study's senior author Dr. Gregg Fonarow, UCLA's Eliot Corday Professor of and Science and director of the Ahmanson–UCLA Cardiomyopathy Center at the David Geffen School of Medicine at UCLA. "Our findings demonstrate the importance of prescribing these -directed medical therapies to ."

The study focused on mild to moderate patients who had weakening function in the heart's left ventricle and symptoms of heart failure, which occurs when the ventricle can no longer pump enough blood to the body's other organs. With the heart's diminishing function, fluid can build-up in the lungs so most patients also take a diuretic.

The team used an advanced statistical model to assess the specific incremental and cumulative health and cost benefit contributions of three medications compared with diuretics alone in the treatment of heart failure patients. The medications studied included angiotensin converting enzyme inhibitors, aldosterone antagonists, and beta blockers.

Researchers found that treatment with one or a combination of these medications was associated with lower costs and higher quality of life when compared to just receiving a diuretic alone. The greatest quality-adjusted life years gained for patients was achieved when all three guideline-directed medications were provided.

The team calculated different scenarios and found that the incremental cost-effectiveness ratio of adding each medication was less than $1,500 per each quality-adjusted life year for patients. In some scenarios, the medications were actually cost-saving where heart failure patients lives were prolonged at lower costs to the .

The study found that up to $14,000 could be spent over a lifetime on a disease management program to improve medication adherence and still be highly cost effective.

For the study, cost-effective interventions were defined as those providing good value with a cost of less than $50,000 per quality-adjusted life year, which is the general standard, according to Fonarow. Cost-saving interventions are those that not only extend life but also actually save money to the health care system. Such interventions are not only more effective, but are less costly.

Fonarow notes that the costs of not effectively taking these key medications would be higher due to increased hospitalizations and need for other interventions.

"Given the high healthcare value provided by these medical therapies for health failure, reducing patient costs for these medications or even providing a financial incentive to promote adherence is likely to be advantageous to patients as well as the health care system," said Fonarow. "Further resources should be allocated to ensure full adherence to guideline directed medical therapies for to improve outcomes, provide high-value care, and minimize health care costs."

The researchers used previous clinical trials and government statistics to help calculate mortality, hospitalization rates, and health care costs used in the model.

Fonarow notes that the study offers broad insight into the cost-effectiveness of these medications and a real-world model would provide an additional perspective.

The costs used in this study were estimates of true costs and the actual costs in different delivery systems may vary.

Explore further: Combined use of recommended heart failure therapies significantly boosts survival odds

Related Stories

Combined use of recommended heart failure therapies significantly boosts survival odds

February 22, 2012
(Medical Xpress) -- A UCLA-led study has found that a combination of several key guideline-recommended therapies for heart failure treatment resulted in an improvment of up to 90 percent in the odds of survival over two years.

Tens of thousands of lives could potentially be saved by key heart failure therapies

June 6, 2011
A national study has found that nearly 68,000 deaths potentially could be prevented each year by optimally implementing key national guideline–recommended therapies, including critical medications and cardiac devices, ...

Heart failure patients have new hope

February 13, 2012
"Despite the increasing number of people affected, the prognosis for patients with heart failure has steadily improved," said Gregg C. Fonarow, M.D, chairman of American Heart Association Hospital Accreditation Science Committee ...

Eliminating co-payments for heart attack medications increases adherence

November 14, 2011
The use of specific medications following a heart attack has been shown to reduce cardiovascular events and mortality, however; while highly effective, the rate of adherence to these medications is poor. Researchers from ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.